![]() |
| Site Navigation | Large Cell Lymphomas |
|
|
"The" Book:
|
| Large Cell Lymphomas (LCL) are
one of the most common types of lymphoma, comprising about 20% to 30% of non-Hodgkin's lymphomas.
The median age is 57, with a range of 10-88 years. Although most frequently seen in
adults, large cell lymphomas are not uncommon in children.
Locations As aggressive lymphomas with a tendency to metastasize (spread |
|||
| to other organs), the majority eventually demonstrate some extranodal (outside the lymph nodes) component, including the gastrointestinal tract, testes, thyroid, skin, breast, central nervous system or bone. Although generally extra-nodal involvement is more common than in follicular lymphomas, the marrow is involved only about 10% of the time. | |||
| Causes The specific cause of most forms of non-Hodgkin's lymphoma is unclear. It is possible that genetics and exposure to viral infections may increase the risk for developing this malignancy. Non-Hodgkin's lymphoma has also been linked to chemotherapy and radiation therapy as a second malignancy resulting from the treatment for certain cancers. There has been investigation into the association of the Epstein-Barr virus (EBV) that causes the mononucleosis infection; as well as the human immunodeficiency virus (HIV), which causes acquired immune deficiency syndrome (AIDS). Other chromosome rearrangements have been seen in non-Hodgkin's lymphoma (all types) that are also thought to promote excessive cell growth. About 20% of the cases have good evidence for a t(14;18), BCL-2 gene rearrangement. Children and adults with other hereditary abnormalities have an increased risk of developing non-Hodgkin's lymphoma, including patients with ataxia telangiectasia, X-linked lymphoproliferative disease, or the Wiskott-Aldrich syndrome. Large Cell Lymphoma Types: A Breakdown
Children LCL accounts for about 20-25% of childhood lymphomas. Combined chemotherapy is standard treatment with the specific type dependent on the cell origin and stage of the disease. Radiation has not been shown to improve survival in stage I or II disease. NCI recommends all children be generally considered for clinical trials and be cared for by a multidisciplinary team of pediatric oncologists. Personal Websites
Further Reading Non-Hodgkin's Lymphomas, Peter M. Mauch (Editor), James O. Armitage (Editor), et al., 2004.
Reference Sources
Non-Hodgkin's Lymphoma Information Pages: Non-Hodgkin's
Lymphomas Childhood Lymphoma Information Pages: Childhood
Lymphoma Home - Gateway to Support and More The Lymphoma Information Network This page is a work in progress - if you have more complete information, references, or other information please contact the author. The author is not in the medical field and does not warrant the correctness of the material on this page or the sites linked - please take online information and consult with your own medical team to make informed decisions. Copyright © 1998-2005 Lymphoma Information
Network - All Rights Reserved |
|||